Evidence map›Paper›PMID 27216065›Full record

ArticleAntimicrobial agents and chemotherapy2016

Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.

Yanmin Hu, Henry Pertinez, Fatima Ortega-Muro, Laura Alameda-Martin, Yingjun Liu, Alessandro Schipani, Geraint Davies, Anthony Coates

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Beyond culturability: VBNC-like and differentially culturableFrontiers in cellular and infection microbiology · 2026
    Review
  2. Article
  3. Eradication of Drug-TolerantMicroorganisms · 2023
    Review
  4. Article
  5. Article
  6. Culture-Free Enumeration ofMicroorganisms · 2022
    Article
  7. Article
  8. Microbiology and molecular biology reviews : MMBR · 2020
    Review
  9. Re-growth ofAntimicrobial agents and chemotherapy · 2019
    Article
  10. Article
  11. Article
  12. Rifamycin action on RNA polymerase in antibiotic-tolerantProceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yanmin HuInstitute for Infection and Immunity, St. George's, University of London, London, United Kingdom ymhu@sgul.ac.uk.
Henry PertinezDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Fatima Ortega-MuroGlaxoSmithKline Research and Development, Diseases of Developing World, Tres Cantos, Madrid, Spain.
Laura Alameda-MartinGlaxoSmithKline Research and Development, Diseases of Developing World, Tres Cantos, Madrid, Spain.
Yingjun LiuInstitute for Infection and Immunity, St. George's, University of London, London, United Kingdom.
Alessandro SchipaniDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Geraint DaviesDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Anthony CoatesInstitute for Infection and Immunity, St. George's, University of London, London, United Kingdom.
St George's, University of London · GBUniversity of Liverpool · GBGlaxoSmithKline (Spain) · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, the most effective tuberculosis control method involves case finding and 6 months of chemotherapy. There is a need to improve our understanding about drug interactions, combination activities, and the ability to remove persistent bacteria using the current regimens, particularly in relation to relapse. We aimed to investigate the therapeutic effects of three main components, rifampin (RMP), isoniazid (INH), and pyrazinamide (PZA), in current drug regimens using a modified version of the Cornell mouse model. We evaluated the posttreatment levels of persistent Mycobacterium tuberculosis in the organs of mice using culture filtrate derived from M. tuberculosis strain H37Rv. When RMP was combined with INH, PZA, or INH-PZA, significant additive activities were observed compared to each of the single-drug treatments. However, the combination of INH and PZA showed a less significant additive effect than either of the drugs used on their own. Apparent culture negativity of mouse organs was achieved at 14 weeks of treatment with RMP-INH, RMP-PZA, and RMP-INH-PZA, but not with INH-PZA, when conventional tests, namely, culture on solid agar and in liquid broth, indicated that the organs were negative for bacteria. The relapse rates for RMP-containing regimens were not significantly different from a 100% relapse rate at the numbers of mice examined in this study. In parallel, we examined the organs for the presence of culture filtrate-dependent persistent bacilli after 14 weeks of treatment. Culture filtrate treatment of the organs revealed persistent M. tuberculosis Modeling of mycobacterial elimination rates and evaluation of culture filtrate-dependent organisms showed promise as surrogate methods for efficient factorial evaluation of drug combinations in tuberculosis in mouse models and should be further evaluated against relapse. The presence of culture filtrate-dependent persistent M. tuberculosis is the likely cause of disease relapse in this modified Cornell mouse model.

Indexed as

AnimalsAntitubercular AgentsDisease Models, AnimalDrug CombinationsFemaleIsoniazidMiceMice, Inbred BALB CMycobacterium tuberculosisPyrazinamideRecurrenceRifampinTuberculosis, PulmonaryAntitubercular AgentsDrug CombinationsIsoniazidPyrazinamideRifampin

Identifiers

PMID27216065
PMCPMC4958161
OpenAlexW2404638523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.